Related Experiment Videos
[Fatal attack in patients with bronchial asthma]
Paltiel Weiner1, Rasmi Magadle, Noa Berar-Yanay
1Department of Medicine, A Hillel-Yaffe Medical Center, Hadera, Israel.
Harefuah
|July 18, 2002
Summary
Despite advances in asthma understanding and treatment, asthma deaths persist. Fatal cases reveal two patient groups: slow-onset (Type I) with airway eosinophilia and rapid-onset (Type II) with neutrophilia.
Area of Science:
- Pulmonary Medicine
- Allergy and Immunology
- Critical Care Medicine
Background:
- Asthma mortality remains a significant public health concern despite advances in pathophysiology, treatment, and education.
- Understanding the distinct clinical pathways leading to fatal asthma exacerbations is crucial for targeted interventions.
Observation:
- Studies of fatal and near-fatal asthma identify two primary patient profiles.
- Type I patients exhibit a "slow onset-late arrival" pattern, characterized by poor asthma control, increased bronchodilator use, delayed medical attention, underutilization of glucocorticosteroids, and airway eosinophilia.
- Type II patients present with a minority of cases, experiencing sudden, unexpected, and rapidly progressive asthma attacks, with airway neutrophilia.
Findings:
- Two distinct phenotypes of fatal asthma attacks have been identified.
- Type I asthma deaths are associated with eosinophilic airway inflammation and a history of suboptimal asthma management.
- Type II asthma deaths are linked to neutrophilic airway inflammation and a rapid, severe clinical course.
Implications:
- Recognizing these distinct patient groups can guide more personalized and effective asthma management strategies.
- Early identification of Type I patients at risk for poor control and Type II patients prone to sudden deterioration is essential.
- Further research into the specific mechanisms driving eosinophilic and neutrophilic inflammation in fatal asthma is warranted.